Table 1 Morphology and clinical features of patients at diagnosis.

From: Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities

        

DYSPLASIA

  

Case #

Age/Sex

Diagnosis at t(3;12)

BM Blasts (%)

PB Blasts (%)

WBC (K/µ)

Hgb (g/dL)

Plt (K/µ)

GRANS

RBC

MEGS

SCT

OS (mo)

3

34.6/M

AML-MRC

91

88

129.5

6.8

68

ND

ND

ND

Allo

150.0

11

32.5/F

AML-MRC

78

74

25.4

8.7

186

Pres1,2,3

Pres1,4,5

Pres8,11

No

15.0

8

54.5/M

Acute Mono Leuk

63

21

113

8.1

74

ND

ND

ND

No

17.3

10

45.3/F

AML-MRC

56

53

2.5

8.3

31

Abs

Abs

Pres8

Allo

15.4

16

65.1/F

t-AML

40

19

2.7

8

54

Pres

Pres

ND

Aut

6.8

18

49.5/M

MPAL

35

45

14.8

9.7

17

Pres1,2

Pres1,5

Pres8

No

4.6

20

78.8/M

AML-MRC

35

31

62.6

8.2

33

Pres1,2

Pres1,5

Pres8

No

0.1

17

27.8/M

AML-MRC

22

0

0.3

9.4

25

ND

ND

ND

Allo

4.8

4

57.3/M

AML-MRC

17

3

1.7

10.3

110

Pres1,2

Pres1,5,4

Pres8

No

5.8

12

59.8/F

AML (NOS)

ND

ND

ND

ND

ND

ND

ND

ND

No

6.1

15

34.7/F

AML-MRC

ND

ND

ND

ND

ND

ND

ND

ND

Allo

4.0

19

36.7/F

AML-MRC

ND

ND

ND

ND

ND

ND

ND

ND

Allo

6.8

2

32.5/F

MDS-EB2

18

1

1.8

7.7

36

ND

ND

ND

No

0.9

9

45.8/M

MDS-EB2

18

2

1.8

11.1

92

ND

Pres5

Pres8,9

Allo

82.3

14

73.3/F

MDS-EB2

10

0

1.93

10.58

112

ND

Pres1,5

Pres8

No

2.3

13

63.7/F

t-MDS

3

1

2.2

9

112

Pres1,3

Pres1,5,6

Pres9,10

Allo

31.0

6

57.0/M

t-MDS

1

0

4

9.8

24

Pres1,3

Pres1,6,7

ND

Aut

11.7

1

57.5/M

CML, BCR-ABL1-positive, BP

58

53

75.9

10.9

221

Abs

Abs

Abs

No

6.5

7

58.3/M

CML, BCR-ABL1-positive, BP

27

16

3.2

8.4

61

ND

ND

ND

No

12.0

5

61.8/F

PMF

4

0

16.2

13.1

89

Pres2,3

Abs

Pres8

No

1.2

  1. M male, F female, Age age at initial diagnosis in years, WBC white blood cells, K 1000, µl microliter, Hgb hemoglobin, g/dl grams per deciliter, Plt platelets, PB peripheral blood, BM bone marrow, Abs dysplasia absent, Pres “dysplastic forms” noted but morphology of dysplasia not described in the report, Pres1 dysplasia with irregular nuclear contours, Pres2 dysplasia with cytoplasmic hypogranularity, Pres3 dysplasia with pseudo-Pelger-Huet forms, Pres4 dysplasia with cytoplasmic vacuoles, Pres5 dysplasia with nuclear cytoplasmic asynchrony, Pres6 dysplasia with megaloblastoid changes, Pres7 dysplasia with basophilic stippling, Pres8 small dysplastic megakaryocytes with nuclear hypolobation, Pres9 dysplastic megakaryocytes with separated nuclear lobes, Pres10 dysplastic megakaryocytes with hypogranulated platelets, Pres11 dysplastic micro-megakaryocyte, SCT hemopoietic stem cell transplant, Aut autologous hematopoietic stem cell transplant, Allo allogeneic hematopoietic stem cell transplant, ND not determined, CML chronic myeloid leukemia, MDS-EB2 myelodysplastic syndrome with excess blasts 2, AML acute myeloid leukemia, AML-MRC acute myeloid leukemia with myelodysplasia-related changes, Acute Mono Leuk acute monoblastic leukemia, PMF primary myelofibrosis, t-MDS therapy-related myelodysplastic syndrome, BP blast phase, NOS not otherwise specified, t-AML therapy-related acute myeloid leukemia, MPAL mixed-phenotype acute leukemia T/myeloid not otherwise specified.
Back to article page